- Home
- SPRY vs AVIR Comparison
SPRY vs AVIR Comparison
Compare SPRY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRY | AVIR |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.8M | 413.1M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPRY | AVIR |
|---|---|---|
| Price | $3.05 | $4.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $24.33 | $8.50 |
| AVG Volume (30 Days) | ★ 1.6M | 271.8K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | N/A | ★ N/A |
| Revenue | $84,278,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $52.57 | N/A |
| Revenue Next Year | $45.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.91 | $2.87 |
| 52 Week High | $13.15 | $6.45 |
Technical Indicators
Market Signals| Indicator | SPRY | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 26.39 | 36.71 |
| Support Level | N/A | $4.06 |
| Resistance Level | $4.55 | $4.69 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 8.82 | 29.70 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.